Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo may boost stem cell harvest for lymphoma patients

NCT ID NCT06520163

Disease control Sponsor: The Affiliated People's Hospital of Ningbo University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a combination of three drugs (etoposide, cytarabine, and PEG-rhG-CSF) works better than standard chemotherapy at collecting enough stem cells for a transplant in people with non-Hodgkin's lymphoma. About 99 participants who are in remission will be randomly assigned to one of two groups. The main goal is to see if more patients in the new drug group can collect a high number of stem cells in a single session.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 99 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2024

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed with non-Hodgkin's lymphoma before enrollment. * Indication for autologous stem cell transplantation (ASCT). * Eastern Cooperative Oncology Group (ECOG) performance status of 0\~1. * Achieved complete remission after multiple courses of chemotherapy. * Life expectancy ≥ 3 months. * Subjects must be able to understand the protocol and sign the informed consent. Exclusion Criteria: * Cardiac function class II or higher or cardiac ejection fraction \< 40%. * Serum direct bilirubin (DBIL) more than twice of the upper limit of normal (ULN). * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) more than three times the upper limit of normal (ULN). * Serum creatinine clearance rate ≤ 50%. * Patients with active infection. * History of prior hematopoietic stem cell mobilization.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hematopoietic stem cell mobilization are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematopoietic stem cell mobilization Non-Hodgkin's lymphoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    17 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dongyang People's Hospital

    RECRUITING

    Dongyang, Zhejiang, China

  • Huzhou central hospital

    RECRUITING

    Huzhou, Zhejiang, China

  • Jinhua Municipal Central Hospital

    RECRUITING

    Jinhua, Zhejiang, China

  • Jinhua People's Hospital

    RECRUITING

    Jinhua, Zhejiang, China

  • Lishui Central Hospital

    RECRUITING

    Lishui, Zhejiang, China

  • Ningbo Medical Center Lihuili Hospital

    RECRUITING

    Ningbo, Zhejiang, China

  • Shaoxing People's Hospital

    RECRUITING

    Shaoxing, Zhejiang, China

  • Shaoxing Second Hospital

    RECRUITING

    Shaoxing, Zhejiang, China

  • Taizhou Central Hospital

    RECRUITING

    Taizhou, Zhejiang, China

  • Taizhou Hospital of Zhejiang Province

    RECRUITING

    Taizhou, Zhejiang, China

  • The Affiliated Hangzhou First People's Hospital

    RECRUITING

    Hangzhou, Zhejiang, 310006, China

  • The Affiliated People's Hospital of Ningbo University

    RECRUITING

    Ningbo, Zhejiang, China

  • The First Affiliated Hospital of Wenzhou Medical University

    RECRUITING

    Wenzhou, China

  • The First Affiliated Hospital, College of Medicine, Zhejiang University

    RECRUITING

    Hangzhou, Zhejiang, China

  • The First Hospital of Jiaxing

    RECRUITING

    Jiaxing, Zhejiang, China

  • The Second Affiliated Hospital of Wenzhou Medical University

    RECRUITING

    Wenzhou, Zhejiang, China

  • Tongde Hospital of Zhejiang Province

    RECRUITING

    Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.